Ligand Pharmaceuticals. has been granted a patent for novel fully human monoclonal antibodies targeting human 4-1BB, which are designed for cancer treatment by modulating immune function. The patent includes methods for antibody generation, validation, and expression, along with specific sequences for the antibody’s binding regions. GlobalData’s report on Ligand Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ligand Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Ligand Pharmaceuticals's grant share as of July 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Monoclonal antibodies targeting human 4-1bb for cancer treatment
The patent US12054554B2 describes an isolated antibody specifically targeting 4-1BB, a protein involved in immune response regulation. The claims detail the structural components of the antibody, including specific sequences for the complementarity-determining regions (CDRs) of both heavy and light chains, identified by SEQ ID numbers. The antibody can be a monoclonal, chimeric, or humanized form and may be fused to various IgG constant regions. Additionally, the patent outlines the properties of the antibody, such as its binding affinity to human, cynomolgus, and mouse 4-1BB, as well as its ability to induce cytokine production and enhance T cell proliferation without cross-reactivity to other immune markers.
Furthermore, the patent includes claims for isolated nucleic acid molecules encoding the variable regions of the antibody, along with vectors and host cells for expression. It also describes a pharmaceutical composition containing the antibody and methods for preparing the antibody through expression in host cells. The claims extend to methods for modulating immune responses in subjects by administering the antibody, as well as the provision of a kit containing the antibody. This patent thus encompasses a comprehensive approach to the development and application of a targeted therapeutic antibody for potential immunological interventions.
To know more about GlobalData’s detailed insights on Ligand Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
